Skip to main content
Premium Trial:

Request an Annual Quote

People In The News: Jul 27, 2012

NEW YORK (GenomeWeb News) – Response Biomedical said this week that its board of directors has appointed Jeffrey Purvin to be CEO and a director, and that Peter Thompson has stepped down from the interim CEO position that he has held for nearly one year. Thompson will remain executive chairman of the company's board of directors.

Purvin has 30 years of experience marketing consumer and medical products, and he is a member of the board of directors, audit committee, and finance committee and chair of the compensation committee at Cardica.


BioTheranostics said this week that it has added Brad Smith, Brian Armstrong, and Francois Valencony to its board of directors, and has hired Mary Jo Mullen and Isaac Bright to its senior management, naming Mullen as chief commercial officer and Bright as VP of corporate development.

Smith is a former vice chairman of LabCorp, Armstrong is chief financial officer for BioMérieux, and Valencony is managing director of Merieux Development.

Mullen formerly held senior sales management positions at LabCorp, through its acquisition of Genzyme Genetics. Bright joins the company from QuantaLife and held corporate and business development leadership posts at Medtronic and an investment banking position at CIBC World Markets.


Molecular Devices has formed its scientific advisory board.

The SAB includes Sean Morrison, Director of the Children's Research Institute and Mary McDermott Cook Chair in Pediatric Genetics at University of Texas Southwestern, and investigator of the Howard Hughes Medical Institute; Tobias Meyer, chair of the department of chemical and systems biology at Stanford University School of Medicine; Paul Johnston, associate professor of the department of pharmaceutical sciences at the University of Pittsburgh; Tobin Dickerson, assistant professor in the department of chemistry at Scripps Research Institute and a founding member of the Worm Institute of Research Medicine; and Pam Hawley-Nelson, associate director for process cell culture at MedImmune.


Empire Genomics has appointed Michael Becich to serve on its scientific advisory board. Becich is a professor and founding chair of the department of biomedical informatics at the University of Pittsburgh School of Medicine and is co-director of the university's Clinical and Translational Science Institute and associate director of the University of Pittsburgh Cancer Institute.


Greg Brown has been named to serve on Genetic Technologies' board of directors as a non-executive director. Brown has 25 years of international business experience as VP of global strategic marketing for Digene, now part of Qiagen; senior global marketing director for Roche Molecular Systems; and as a board member at ImpediMed, among other posts.


Rebecca Rimel has been elected to Becton Dickinson's board of directors. Rimel is president and CEO of the Pew Charitable Trusts, a large public charity, a position she has held since 1994.


Rosetta Genomics said this week in a filing with the Securities and Exchange Commission that Ranit Aharonov-Gal has tendered her resignation from her position as executive VP of R&D to pursue other opportunities. Her resignation will be effective on Oct. 21.


Pacific Biosciences has named David Botstein to its board of directors.

Botstein is director of the Lewis-Sigler Institute for Integrative Genomics and Anthony B. Evnin Professor of Genomics at Princeton University, a position he has held since 2003. Previously, he was chairman of the department of genetics at Stanford University and before that he served as vice president for science at Genentech, where he currently serves on the company's scientific resource board.


Hugh Martin, former president and CEO of Pacific Biosciences, is now chairman and CEO of Xeralux, a manufacturer of LED retrofit kits. He joined the firm in April of this year. Martin led PacBio from 2004 until January of this year, when he resigned and was replaced by Michael Hunkapiller. He resigned from the company's board in April.


Opko Health has appointed Juan Rodriguez as senior vice president and chief financial officer.

Rodriguez was previously a consultant to software firm Cognitec Systems. Before that he held a number of executive positions at Kos Pharmaceuticals, which was acquired in 2007 by Abbott Laboratories.


Firefly BioWorks said Victor Ambros has been elected to its scientific advisory board. Ambros is the Silverman Professor of Natural Sciences in the Program in Molecular Medicine at the University of Massachusetts Medical School. He also is co-director of the RNA Therapeutics Institute at the medical school.


Promoted? Changing jobs? GenomeWeb wants to know. [email protected] to appear in People In The News, a weekly roundup of industry comings and goings.

The Scan

Looking for Omicron

NPR reports that SARS-CoV-2 testing in the US has gotten better but also that some experts say more needs to be done to better track the Omicron variant.

Holmes Alleges Abuse

The Associated Press reports that Theranos' Elizabeth Holmes has testified at her wire fraud trial that her business and romantic partner abused her.

Bit More Diverse, But More to Do

While Black and Hispanic patients are more likely to participate in cancer clinical trials than previously, they are still underrepresented, according to US News & World Report.

PNAS Papers on Yeast Gene Silencing, Zika Virus Inhibition, Immunoglobulin Hypermutation

In PNAS this week: gene silencing in Saccharomyces cerevisiae, possible neuroprotective role for SHFL in a mouse model of Zika virus infection, and more.